UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the target of a large growth in short interest in January. As of January 15th, there was short interest totalling 4,700 shares, a growth of 2,250.0% from the December 31st total of 200 shares. Based on an average trading volume of 13,700 shares, the short-interest ratio is currently 0.3 days.

UCB Stock Up 0.7 %

Shares of UCBJY stock traded up $0.66 during trading hours on Wednesday, reaching $98.88. 5,757 shares of the stock were exchanged, compared to its average volume of 7,263. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. UCB has a 12-month low of $46.00 and a 12-month high of $100.66. The company’s 50-day moving average price is $97.18 and its 200-day moving average price is $92.14.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.